ClearBridge Investments
NBIX icon

ClearBridge Investments’s Neurocrine Biosciences NBIX Stock Holding History

ClearBridge Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.4M Sell
281,194
-28,841
-9% -$4.28M 0.04% 335
2026
Q1 		$40.8M Sell
310,035
-42
-0% -$5.57K 0.04% 341
2025
Q4 		$44M Sell
310,077
-26,859
-8% -$3.89M 0.04% 343
2025
Q3 		$47.3M Sell
336,936
-5,366
-2% -$727K 0.04% 335
2025
Q2 		$43M Hold
342,302
– – 0.03% 327
2025
Q1 		$37.9M Buy
342,302
+23,003
+7% +$2.91M 0.03% 343
2024
Q4 		$43.6M Hold
319,299
– – 0.04% 340
2024
Q3 		$36.8M Sell
319,299
-21,503
-6% -$2.95M 0.03% 370
2024
Q2 		$46.9M Hold
340,802
– – 0.04% 327
2024
Q1 		$47M Hold
340,802
– – 0.04% 345
2023
Q4 		$44.9M Buy
340,802
+28,805
+9% +$3.32M 0.04% 343
2023
Q3 		$35.1M Hold
311,997
– – 0.03% 356
2023
Q2 		$29.4M Buy
311,997
+61,210
+24% +$5.98M 0.03% 387
2023
Q1 		$25.4M Hold
250,787
– – 0.02% 402
2022
Q4 		$30M Hold
250,787
– – 0.03% 390
2022
Q3 		$26.6M Hold
250,787
– – 0.03% 396
2022
Q2 		$24.4M Sell
250,787
-5
-0% -$461 0.02% 414
2022
Q1 		$23.5M Hold
250,792
– – 0.02% 446
2021
Q4 		$21.4M Sell
250,792
-1,058
-0.4% -$97.3K 0.01% 467
2021
Q3 		$24.2M Sell
251,850
-50
-0% -$4.72K 0.02% 461
2021
Q2 		$24.5M Sell
251,900
-40
-0% -$3.83K 0.02% 478
2021
Q1 		$24.5M Buy
251,940
+40,410
+19% +$4.24M 0.02% 455
2020
Q4 		$20.3M Sell
211,530
-7,970
-4% -$770K 0.02% 466
2020
Q3 		$21.1M Buy
+219,500
New +$25.4M 0.02% 416

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ClearBridge Investments's NBIX Position: Q2 2026 in Review

ClearBridge Investments reduced its Neurocrine Biosciences (NBIX) stake by 9.3% in Q2 2026, selling an estimated $4.28M and leaving 281,194 shares worth $47.4M. The position accounts for 0.04% of the portfolio, ranked #335.

ClearBridge Investments first reported a position in NBIX in Q3 2020 and has held it in 24 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • ClearBridge Investments held 281,194 shares of Neurocrine Biosciences worth $47.4M as of Q2 2026.
  • ClearBridge Investments sold 28,841 Neurocrine Biosciences shares in Q2 2026, an estimated $4.28M.
  • Neurocrine Biosciences made up 0.04% of ClearBridge Investments's portfolio in Q2 2026, its #335 holding.
  • ClearBridge Investments first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 24 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.